HNP-1 vs Mifamurtide
Head-to-head comparison of HNP-1 (Human Neutrophil Peptide 1 (Alpha-Defensin 1)) and Mifamurtide (Muramyl Tripeptide Phosphatidylethanolamine) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | HNP-1 | Mifamurtide |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Human Neutrophil Peptide 1 (Alpha-Defensin 1) | Muramyl Tripeptide Phosphatidylethanolamine |
| Molecular Weight | 3443 Da | N/A |
| Half-Life | Minutes to hours; protease-sensitive | 2-4 h |
| Amino Acids | 30 | N/A |
| Typical Dose | Research use only; no approved human dose | 2 mg/m2 |
| Route | Topical / Research parenteral | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 610 | 150 |
| Research Status | Pre-clinical | Clinical |
HNP-1 Benefits
- ✓neutrophil-derived antimicrobial defense
- ✓broad pathogen killing
- ✓immune cell signaling
- ✓mucosal protection
Mifamurtide Benefits
- ✓macrophage-activation
- ✓innate-immune-signaling
- ✓immune-adjuvant-research
- ✓cytokine-response
HNP-1 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Mifamurtide Dosing
2 mg/m2 IV|2x weekly for 12 weeks|then weekly for 24 weeks in approved regimens
HNP-1 Side Effects
- ⚠membrane toxicity at high concentrations
- ⚠short in vivo stability
- ⚠potential inflammation amplification
Mifamurtide Side Effects
- ⚠fever/chills
- ⚠fatigue
- ⚠nausea
Research Overview
HNP-1
HNP-1 has been studied as a key component of neutrophil-mediated host defense against bacteria, fungi, and some enveloped viruses. Literature also reports immunomodulatory effects, including impacts on chemotaxis, cytokine release, and barrier defense.
Mifamurtide
Mifamurtide has substantial literature as an innate immune activator and is an approved oncology adjunct in some regions. Research centers on NOD-like receptor signaling, macrophage activation, and downstream cytokine effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.